NTI

NEUROTECH FPO [NTI]
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0180 +12.5%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when NTI triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track NTI — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Trading above both moving averages — the trend is your friend here
  • Volume surging at 4.0x normal while price climbs — real buying conviction behind this move
  • Beating the Small Ords index — relative strength of 1.49, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (9 quarters)
  • Low P/S ratio (3.0x)
  • Strong revenue growth (+4069%)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +4069% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (3.02%/day)
  • Altman Z-Score grey zone (2.03, low-confidence approx)
  • Penny stock risk ($0.016)
  • RBA hiking (-3pts)
  • Dilution risk: technical breakout with recent capital raise
  • Calendar: Quarterly 4C in 12d (+5pts)

Risk Signals

  • Deeply negative margins (-54%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 26% over the past year
Ask Scout AI about NTI
"What's driving NTI today?" "How does NTI compare to peers?" "Key risks for NTI?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Neurotech secures $3.15 million R&D tax incentive loan
NONE US FDA clears IND for NTI164
NONE Notification regarding unquoted securities - NTI
Announcement tone +3pts

Recent ASX Announcements

2026-07-15 Neurotech secures $3.15 million R&D tax incentive loan PRICE SENSITIVE
2026-07-13 US FDA clears IND for NTI164 PRICE SENSITIVE
2026-07-13 Notification regarding unquoted securities - NTI
2026-07-12 Proposed issue of securities - NTI
2026-07-01 NTI secures Notices of Allowance for US patent applications PRICE SENSITIVE

Key Metrics

$21.1M
Market Cap
2.5M
Avg Volume
4.0x
Vol Ratio
$0.01 — $0.03
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-66.3%
ROE
-54.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 75%
LLeader vs LaggardpassRS: 14
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%PIQ -11.4%OSL -10.3%TRJ -10.2%
Compare:NTI vs ECSNTI vs VHLNTI vs PIQ
Scout Pro — Deeper Analysis for NTI
Try Pro free for 30 days
Share this analysis

Track NTI and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required